CLNN - Clene Inc. Stock Price, Fair Value and News

0.34USD0.00 (0.00%)Market Closed

Market Summary

USD0.340.00

Market Closed

0.00%

CLNN Stock Price

View Fullscreen

CLNN RSI Chart

CLNN Valuation

Market Cap

43.7M

Price/Earnings (Trailing)

-0.88

Price/Sales (Trailing)

66.77

EV/EBITDA

-0.34

Price/Free Cashflow

-1.43

CLNN Price/Sales (Trailing)

CLNN Profitability

Operating Margin

81.50%

EBT Margin

-7569.42%

Return on Equity

-369.71%

Return on Assets

-94.58%

Free Cashflow Yield

-69.85%

CLNN Fundamentals

CLNN Revenue

Revenue (TTM)

654.0K

Rev. Growth (Yr)

-27.35%

Rev. Growth (Qtr)

57.41%

CLNN Earnings

Earnings (TTM)

-49.5M

Earnings Growth (Yr)

-865.18%

Earnings Growth (Qtr)

-320.72%

Breaking Down CLNN Revenue

Last 30 days

-20.9%

Last 90 days

-35.8%

Trailing 12 Months

-64.2%

How does CLNN drawdown profile look like?

CLNN Financial Health

Current Ratio

1.53

CLNN Investor Care

Shares Dilution (1Y)

73.96%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	550.0K	784.0K	718.0K	654.0K
2022	540.0K	374.0K	438.0K	473.0K
2021	349.0K	541.0K	553.0K	723.0K
2020	0	0	0	206.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Clene Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 09, 2024	general resonance llc	sold	-8,674	0.385533	-22,500	-
Nov 10, 2023	matlin david j	bought	102,501	0.41	250,002	-
Jun 26, 2023	stevens john henry	bought	253,164	0.8	316,455	-
Jun 26, 2023	etherington robert dee	bought	20,250	0.81	25,000	chief executive officer
Jun 16, 2023	mosca alison	bought	1,915,500	0.8	2,394,380	-
Jun 16, 2023	gay jonathon	bought	84,500	0.8	105,625	-
Jun 16, 2023	ugwumba chidozie	bought	6,000,000	0.8	7,500,000	-
Jun 16, 2023	matlin david j	bought	1,200,000	0.8	1,500,000	-
Dec 31, 2022	ugwumba chidozie	acquired	-	-	1,019,210	-
Nov 14, 2022	wilcox reed n	acquired	26,236	0.15	174,912	-

Which funds bought or sold CLNN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	WASHINGTON TRUST Co	unchanged	-	386	1,276	-%
Apr 23, 2024	Lunt Capital Management, Inc.	unchanged	-	66,057	218,172	0.11%
Apr 19, 2024	Cutler Group LLC / CA	unchanged	-	-	1,000	-%
Apr 19, 2024	Realta Investment Advisors	unchanged	-	2,060	6,806	-%
Apr 15, 2024	Pallas Capital Advisors LLC	unchanged	-	2,234	7,377	-%
Apr 15, 2024	Key Client Fiduciary Advisors, LLC	unchanged	-	3,348	11,060	0.01%
Apr 10, 2024	Partnership Wealth Management, LLC	unchanged	-	-2,572	15,953	0.01%
Mar 11, 2024	VANGUARD GROUP INC	added	7.05	-436,316	776,614	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	unchanged	-	-54.00	82.00	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	6,656	6,656	-%

Are Funds Buying or Selling CLNN?

Are funds buying CLNN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CLNN

No. of Funds

Unveiling Clene Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	mosca alison	9.6%	12,857,926	SC 13G/A
Feb 14, 2024	awm investment company, inc.	9.2%	12,691,213	SC 13G
Feb 14, 2024	citadel advisors llc	4.3%	6	SC 13G/A
Feb 13, 2024	vivo opportunity fund holdings, l.p.	7.0%	12,500,000	SC 13G/A
Sep 11, 2023	ugwumba chidozie	19.9%	28,018,908	SC 13G
Jul 03, 2023	citadel advisors llc	5.7%	6	SC 13G
Jun 28, 2023	vivo opportunity fund holdings, l.p.	9.99%	17,737,800	SC 13G
Jun 20, 2023	matlin david j	5.6%	7,146,990	SC 13D/A
Feb 21, 2023	matlin david j	7.6%	5,604,362	SC 13D/A
Feb 17, 2023	foley & lardner/ fa	7.6%	5,601,862	SC 13D/A

Recent SEC filings of Clene Inc.

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	ARS	ARS
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	8-K	Current Report
Apr 16, 2024	DEF 14A	DEF 14A
Apr 16, 2024	DEFA14A	DEFA14A
Apr 09, 2024	8-K	Current Report
Apr 05, 2024	PRE 14A	PRE 14A
Mar 13, 2024	10-K	Annual Report
Mar 13, 2024	8-K	Current Report
Mar 12, 2024	4	Insider Trading

Peers (Alternatives to Clene Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Clene Inc. News

Latest updates

Clene Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	57.4%	170,000	108,000	269,000	107,000	234,000	174,000	35,000	30,000	199,000	110,000	201,000	213,000	29,000	98,000	9,000	70,000
Cost Of Revenue	216.7%	38,000	12,000	66,000	5,000	7,000	19,000	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	4.7%	10,100,000	9,650,000	10,605,000	10,839,000	11,907,000	9,979,000	13,630,000	13,366,000	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	9,979,000	13,630,000	13,366,000	14,257,000	10,560,000	13,976,000	11,908,000	5,989,000	5,789,000	4,570,000	4,072,000
S&GA Expenses	-7.6%	3,389,000	3,666,000	3,924,000	3,439,000	4,129,000	3,557,000	4,464,000	4,786,000	5,257,000	4,400,000	6,949,000	5,390,000	1,528,000	1,795,000	1,016,000	812,000
R&D Expenses	11.7%	6,673,000	5,972,000	6,615,000	7,395,000	7,771,000	6,403,000	9,166,000	8,580,000	9,523,000	6,146,000	6,472,000	6,275,000	4,454,000	3,994,000	3,554,000	3,202,000
EBITDA Margin	-15.4%	-66.12	-57.28	-64.06	-54.76	-68.07	-50.87	44.91	31.76	-13.15	-20.40	-93.25	-151	-82.32	-	-	-
Interest Expenses	1.0%	1,200,000	1,188,000	1,104,000	1,066,000	906,000	857,000	751,000	782,000	-950,000	80,000	26,000	551,000	-	-	190,000	51,000
Income Taxes	-	-	-	-	-	-	-	-	-	-215,000	-69,000	-72,000	-72,000	-	-	-	-
Earnings Before Taxes	-320.7%	-10,173,000	-2,418,000	-25,143,000	-11,770,000	-1,054,000	-10,976,000	-4,534,000	-13,354,000	4,208,000	28,875,000	-3,423,000	-39,828,000	1,184,000	-10,295,000	-5,819,000	-3,941,000
EBT Margin	-34.6%	-75.69	-56.25	-62.43	-51.52	-63.25	-56.29	40.63	30.20	-14.06	-23.86	-96.79	-156	-91.61	-	-	-
Net Income	-320.7%	-10,173,000	-2,418,000	-25,143,000	-11,770,000	-1,054,000	-10,976,000	-4,534,000	-13,354,000	4,423,000	28,944,000	-3,351,000	-39,756,000	778,000	-10,295,000	-5,819,000	-3,941,000
Net Income Margin	-34.6%	-75.69	-56.25	-62.43	-51.52	-63.25	-55.80	41.39	30.86	-13.47	-24.20	-97.28	-157	-93.59	-	-	-
Free Cashflow	-6.0%	-7,215,000	-6,809,000	-7,000,000	-9,478,000	-9,406,000	-10,135,000	-10,602,000	-14,036,000	-10,277,000	-7,559,000	-8,717,000	-9,403,000	-5,918,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-13.4%	52.00	60.00	68.00	40.00	44.00	36.00	45.00	53.00	63.00	73.00	73.00	59.00	68.00	15.00
Current Assets	-16.4%	39.00	46.00	53.00	25.00	29.00	21.00	32.00	42.00	55.00	65.00	68.00	53.00	63.00	9.00
Cash Equivalents	-31.6%	29.00	42.00	49.00	18.00	18.00	7.00	7.00	13.00	50.00	61.00	63.00	48.00	59.00	9.00
Inventory	-64.4%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net PPE	-	-	-	-	-	-	10.00	8.00	6.00	5.00	4.00	4.00	4.00	4.00	4.00
Liabilities	-0.2%	39.00	39.00	46.00	42.00	41.00	45.00	45.00	51.00	50.00	67.00	99.00	95.00	68.00	10.00
Current Liabilities	65.9%	25.00	15.00	6.00	17.00	14.00	6.00	8.00	5.00	6.00	5.00	5.00	4.00	12.00	4.00
LT Debt, Current	-	5.00	-	-	-	-	-	-	-	-	-	-	-	6.00	-
Shareholder's Equity	-37.4%	13.00	21.00	22.00	-	3.00	-	-	2.00	13.00	6.00	-	-	0.00	-
Retained Earnings	-4.4%	-242	-232	-230	-205	-193	-192	-181	-176	-163	-167	-196	-193	-153	-69.57
Additional Paid-In Capital	0.8%	256	254	251	203	196	183	181	178	176	173	170	157	154	2.00
Shares Outstanding	0.0%	128	128	128	78.00	75.00	64.00	63.00	63.00	62.00	62.00	61.00	61.00	-	-
Float	-	-	-	78.00	-	-	-	85.00	-	-	-	360	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-5.5%	-7,172	-6,799	-7,000	-9,200	-7,711	-8,486	-9,730	-13,084	-9,582	-7,318	-8,500	-9,200	-5,800	-7,698	-2,151	-3,251	-
Share Based Compensation	-14.6%	2,047	2,396	2,451	2,223	2,029	2,098	2,184	2,202	2,439	2,425	4,255	3,265	207	209	174	171	-
Cashflow From Investing	-12841.7%	-6,212	-48.00	39.00	4,722	2,282	8,411	3,665	-24,522	-671	-241	-217	-203	-118	-75.00	-171	-23.00	-
Cashflow From Financing	92.4%	-18.00	-237	37,830	4,588	16,374	92.00	548	235	-18.00	5,232	23,794	-1,896	28,170	37,696	2,121	1,547	-

CLNN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 654	$ 473
Operating expenses:
Cost of revenue	121	26
Research and development	26,655	31,920
General and administrative	14,418	16,936
Total operating expenses	41,194	48,882
Loss from operations	(40,540)	(48,409)
Other income (expense), net:
Interest income	1,389	225
Interest expense	(4,558)	(3,296)
Gain on termination of lease	0	420
Commitment share expense	(402)	0
Issuance costs for common stock warrant liabilities	(333)	0
Loss on initial issuance of equity	(14,840)	0
Change in fair value of common stock warrant liabilities	6,337	169
Change in fair value of Clene Nanomedicine contingent earn-out liability	2,189	15,836
Change in fair value of Initial Stockholders contingent earn-out liability	281	2,026
Research and development tax credits and unrestricted grants	963	3,079
Other income, net	10	32
Total other income (expense), net	(8,964)	18,491
Net loss before income taxes	(49,504)	(29,918)
Income tax benefit	0	0
Net loss	(49,504)	(29,918)
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities	16	(14)
Foreign currency translation adjustments	(20)	(16)
Total other comprehensive loss	(4)	(30)
Comprehensive loss	$ (49,508)	$ (29,948)
Net loss per share – basic and diluted (in dollars per share)	$ (0.47)	$ (0.46)
Weighted average common shares used to compute basic and diluted net loss per share (in shares)	104,938,819	65,204,663
Product [Member]
Revenue:
Total revenue	$ 498	$ 329
Royalty [Member]
Revenue:
Total revenue	$ 156	$ 144

CLNN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 28,821	$ 18,332
Marketable securities	6,179	4,983
Accounts receivable	143	189
Inventory	37	43
Prepaid expenses and other current assets	3,672	5,648
Total current assets	38,852	29,195
Restricted cash	58	58
Operating lease right-of-use assets	4,168	4,602
Property and equipment, net	9,263	10,638
TOTAL ASSETS	52,341	44,493
Current liabilities:
Accounts payable	1,504	3,014
Accrued liabilities	3,720	3,863
Operating lease obligations, current portion	576	488
Finance lease obligations, current portion	27	74
Notes payable, current portion	14,627	6,418
Convertible notes payable, current portion	4,876	0
Total current liabilities	25,330	13,857
Operating lease obligations, net of current portion	4,903	5,557
Finance lease obligations, net of current portion	0	34
Notes payable, net of current portion	1,894	9,483
Convertible notes payable, net of current portion	5,258	9,770
Common stock warrant liabilities	1,481	0
Clene Nanomedicine contingent earn-out liability	75	2,264
Initial Stockholders contingent earn-out liability	10	291
TOTAL LIABILITIES	38,951	41,256
Commitments and contingencies (Note 9)
Stockholders’ equity:
Common stock, $0.0001 par value: 300,000,000 and 150,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 128,422,851 and 74,759,591 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	13	7
Additional paid-in capital	255,901	196,246
Accumulated deficit	(242,723)	(193,219)
Accumulated other comprehensive income	199	203
TOTAL STOCKHOLDERS’ EQUITY	13,390	3,237
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 52,341	$ 44,493

About Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

CEO	Mr. Robert Etherington MBA
WEBSITE	https://clene.com
INDUSTRY	Biotechnology
EMPLOYEES	75

Clene Inc. Frequently Asked Questions

What is the ticker symbol for Clene Inc.? What does CLNN stand for in stocks?

CLNN is the stock ticker symbol of Clene Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Clene Inc. (CLNN)?

As of Wed Apr 24 2024, market cap of Clene Inc. is 43.67 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLNN stock?

You can check CLNN's fair value in chart for subscribers.

What is the fair value of CLNN stock?

You can check CLNN's fair value in chart for subscribers. The fair value of Clene Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Clene Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLNN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Clene Inc. a good stock to buy?

The fair value guage provides a quick view whether CLNN is over valued or under valued. Whether Clene Inc. is cheap or expensive depends on the assumptions which impact Clene Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLNN.

What is Clene Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, CLNN's PE ratio (Price to Earnings) is -0.88 and Price to Sales (PS) ratio is 66.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLNN PE ratio will change depending on the future growth rate expectations of investors.